Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol 2016;34:2925–2934.

• Crossref
• PubMed
Schnipper LE, Davidson NE, Wollins DS, Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol 2016;34:2925–2934.10.1200/JCO.2016.68.2518)| false
• Search Google Scholar
• Export Citation

Cheng S, Cheung MC, Jiang DM, et al. Are surrogate endpoints unbiased metrics in clinical benefit scores of the ASCO Value Framework? J Natl Compr Canc Netw 2019;17:1489–1496.

• Crossref
• PubMed
Cheng S, Cheung MC, Jiang DM, Are surrogate endpoints unbiased metrics in clinical benefit scores of the ASCO Value Framework? J Natl Compr Canc Netw 2019;17:1489–1496.10.6004/jnccn.2019.733331805528)| false
• Search Google Scholar
• Export Citation

Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 2015;175:1992–1994.

• Crossref
• PubMed
Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 2015;175:1992–1994.10.1001/jamainternmed.2015.586826502403)| false
• Search Google Scholar
• Export Citation

Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern Med 2019;179:915–921.

• Crossref
• PubMed
Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern Med 2019;179:915–921.10.1001/jamainternmed.2019.058331135822)| false
• Search Google Scholar
• Export Citation

Chen EY, Joshi SK, Tran A, Prasad V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern Med 2019;179:642–647.

• Crossref
• PubMed
Chen EY, Joshi SK, Tran A, Prasad V. Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials. JAMA Intern Med 2019;179:642–647.10.1001/jamainternmed.2018.835130933235)| false
• Search Google Scholar
• Export Citation

Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer 2019;106:196–211.

• Crossref
• PubMed
Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer 2019;106:196–211.10.1016/j.ejca.2018.11.01230528804)| false
• Search Google Scholar
• Export Citation

Kay A, Higgins J, Day AG, et al. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Ann Oncol 2012;23:1646–1651.

• Crossref
• PubMed
Kay A, Higgins J, Day AG, Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Ann Oncol 2012;23:1646–1651.10.1093/annonc/mdr49222048151)| false
• Search Google Scholar
• Export Citation

Saluja R, Everest L, Cheng S, et al. Assessment of whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale measure absolute or relative clinical survival benefit: a meta-analysis of randomized clinical trials [published online May 16, 2019]. JAMA Oncol. doi: 10.1001/jamaoncol.2019.0818

• PubMed
Saluja R, Everest L, Cheng S, Assessment of whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale measure absolute or relative clinical survival benefit: a meta-analysis of randomized clinical trials [published online May 16, 2019]. JAMA Oncol. doi: 10.1001/jamaoncol.2019.0818)| false
• Search Google Scholar
• Export Citation

Seymour EK, Schiffer CA, de Souza JA. Challenges in the clinical application of the American Society of Clinical Oncology Value Framework: a Medicare cost-benefit analysis in chronic lymphocytic leukemia. J Oncol Pract 2017;13:e1002–1011.

• Crossref
• PubMed
Seymour EK, Schiffer CA, de Souza JA. Challenges in the clinical application of the American Society of Clinical Oncology Value Framework: a Medicare cost-benefit analysis in chronic lymphocytic leukemia. J Oncol Pract 2017;13:e1002–1011.10.1200/JOP.2017.024778)| false
• Search Google Scholar
• Export Citation

Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol 2016;27:373–378.

• Crossref
• PubMed
Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol 2016;27:373–378.10.1093/annonc/mdv56226578738)| false
• Search Google Scholar
• Export Citation